Genetic Variation in the SLC19A1 gene and Methotrexate Toxicity in Rheumatoid Arthritis Patients
We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach. Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect...
Saved in:
Published in | Pharmacogenomics Vol. 13; no. 14; pp. 1583 - 1594 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Future Medicine Ltd
01.11.2012
|
Subjects | |
Online Access | Get full text |
ISSN | 1462-2416 1744-8042 1744-8042 |
DOI | 10.2217/pgs.12.150 |
Cover
Abstract | We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach.
Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation.
Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant.
Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed. |
---|---|
AbstractList | Aim: We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach. Patients & methods: Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation. Results: Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant. Conclusion: Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed. Original submitted 23 May 2012; Revision submitted 3 September 2012 We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach.AIMWe investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach.Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation.PATIENTS & METHODSTwo hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation.Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant.RESULTSTwo putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant.Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed.CONCLUSIONIndividual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed. Original submitted 23 May 2012; Revision submitted 3 September 2012 We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach. Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation. Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant. Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed. |
Audience | Academic |
Author | Inglada-Pérez, Lucía Logar, Dušan Rodríguez-Antona, Cristina Bohanec Grabar, Petra Dolžan, Vita Leandro-García, Luis J |
Author_xml | – sequence: 1 givenname: Petra surname: Bohanec Grabar fullname: Bohanec Grabar, Petra organization: Pharmacogenetics Laboratory, Institute of Biochemistry, University of Ljubljana, Vrazov trg 2, 1000Ljubljana, Slovenia – sequence: 2 givenname: Luis J surname: Leandro-García fullname: Leandro-García, Luis J organization: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Center, Madrid, Spain – sequence: 3 givenname: Lucía surname: Inglada-Pérez fullname: Inglada-Pérez, Lucía organization: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Center, Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain – sequence: 4 givenname: Dušan surname: Logar fullname: Logar, Dušan organization: Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, Ljubljana, Slovenia – sequence: 5 givenname: Cristina surname: Rodríguez-Antona fullname: Rodríguez-Antona, Cristina organization: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Center, Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain – sequence: 6 givenname: Vita surname: Dolžan fullname: Dolžan, Vita organization: Pharmacogenetics Laboratory, Institute of Biochemistry, University of Ljubljana, Vrazov trg 2, 1000Ljubljana, Slovenia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23148635$$D View this record in MEDLINE/PubMed |
BookMark | eNqN0ltrFDEUAOAgFXvRF3-ABHwpwqw5ucxkHpfFVmGlRauvMTOT2U2ZyaxJBtp_71lbFUtByUNC8uXkcs4xOQhTcIS8BLbgHKq3u01aAF-AYk_IEVRSFppJfoBjWfKCSygPyXFK14xxKCV7Rg65AKlLoY7It3MXXPYt_Wqjt9lPgfpA89bRz-sV1EugGwTUho5-dHk75ehubHb0arrxrc-3e_1p6-bR5sl3dBnzNvrsE73EYC7k9Jw87e2Q3Iv7_oR8OXt3tXpfrC_OP6yW66KVUufC9lzYRkHV9Ax72SlXa91qCayy2lred7jeibqvlGx6XTeibFQDWne8VcKKE3J6F3cXp--zS9mMPrVuGGxw05wMCK4VCC3Vf1ImoPw3hQp0BSWXSF8_oNfTHAO-GRU-rJZ1Xf5RGzs440OPP2rbfVCzFExzIYSuUC0eUdg6N_oWs997nP9rw6v7w-dmdJ3ZRT_aeGt-JRrBmzvQximl6PrfBJjZV5HBKjLADVYRYvYAY6p_Fgdeww-PbfkB0F_GRw |
CitedBy_id | crossref_primary_10_1080_17460441_2020_1682992 crossref_primary_10_1111_cts_70136 crossref_primary_10_2217_pgs_14_116 crossref_primary_10_1016_j_gpb_2016_11_003 crossref_primary_10_1515_raon_2017_0040 crossref_primary_10_3389_fphar_2018_00020 crossref_primary_10_1517_17425255_2016_1121233 crossref_primary_10_1080_17425255_2020_1777279 crossref_primary_10_1093_toxsci_kfu162 crossref_primary_10_1002_mgg3_884 crossref_primary_10_2217_pgs_2016_0158 crossref_primary_10_3390_diagnostics12071560 crossref_primary_10_2217_pgs_2016_0067 crossref_primary_10_1007_s00280_022_04405_7 crossref_primary_10_1038_tpj_2016_36 crossref_primary_10_2217_pgs_14_25 crossref_primary_10_2217_pgs_13_244 crossref_primary_10_3390_cimb46100685 crossref_primary_10_1016_j_intimp_2016_05_012 crossref_primary_10_1016_j_lfs_2020_118907 crossref_primary_10_3390_ijms160613760 crossref_primary_10_1007_s12026_014_8564_6 crossref_primary_10_1111_cge_13186 crossref_primary_10_1007_s00439_019_02081_x |
Cites_doi | 10.1002/art.21573 10.1186/1471-2105-9-557 10.1038/sj.tpj.6500438 10.1093/rheumatology/41.12.1367 10.1200/JCO.2008.20.4156 10.1006/mgme.2000.3034 10.1186/1477-7525-1-20 10.1038/ng1001-233 10.1002/art.20460 10.1038/tpj.2012.7 10.1006/meth.2001.1262 10.1007/s00228-008-0521-7 10.1159/000180580 10.1093/bioinformatics/bth457 10.1007/s00296-007-0339-0 10.1097/FPC.0b013e32833315d1 10.1002/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO;2-B 10.1186/ar419 10.1093/nar/16.3.1215 10.1097/00008571-200204000-00002 10.1042/bj20020512 10.1093/rheumatology/39.9.975 10.1002/art.21726 10.1002/art.22129 10.1097/01.fpc.0000236326.80809.b1 10.1136/ard.2009.111567 10.1002/art.1780310302 10.1023/B:SCAM.0000007117.50428.63 10.1136/ard.59.suppl_1.i28 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2012 Future Medicine Ltd. 2012 Future Medicine Ltd |
Copyright_xml | – notice: COPYRIGHT 2012 Future Medicine Ltd. – notice: 2012 Future Medicine Ltd |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO EHMNL FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 8FD FR3 P64 RC3 7U7 C1K |
DOI | 10.2217/pgs.12.150 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central UK & Ireland Database (ProQuest) Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library UK & Ireland Database ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE - Academic ProQuest Central Student Genetics Abstracts Genetics Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1744-8042 |
EndPage | 1594 |
ExternalDocumentID | 2815046481 A308233387 23148635 10_2217_pgs_12_150 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Slovenia Spain |
GeographicLocations_xml | – name: Slovenia – name: Spain |
GroupedDBID | --- 0R~ 0VX 123 29O 4.4 53G 70G 7X7 88E 8AO 8FE 8FH 8FI 8FJ AAWFG AAYOK AAYXX ABJNI ABUWG ACGFS ACPRK ACWKX ADBBV AENEX AFFYO AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION CS3 DU5 EBS EHMNL EJD F5P FYUFA H13 HCIFZ HMCUK HZ~ IAO IEA IHR ITC LK8 M1P M4Z M7P MV1 NTCAX O9- OVD P2P PHGZM PHGZT PQQKQ PROAC PSQYO RPM TDBHL TEORI TFL TFMDE TMEDX UKHRP CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK ABNDM AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 PUEGO 8FD FR3 P64 RC3 7U7 C1K |
ID | FETCH-LOGICAL-c448t-af23ab517bf0ab54d5e988c84107a8aa2fd3abd39f754bf89b36b5b188d2c53a3 |
IEDL.DBID | 7X7 |
ISSN | 1462-2416 1744-8042 |
IngestDate | Fri Sep 05 03:38:19 EDT 2025 Thu Sep 04 23:32:39 EDT 2025 Thu Sep 04 19:47:50 EDT 2025 Fri Jul 25 18:57:39 EDT 2025 Tue Jun 17 21:25:01 EDT 2025 Tue Jun 10 20:30:12 EDT 2025 Thu Apr 03 06:53:48 EDT 2025 Tue Jul 01 01:07:49 EDT 2025 Thu Apr 24 23:14:41 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 14 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c448t-af23ab517bf0ab54d5e988c84107a8aa2fd3abd39f754bf89b36b5b188d2c53a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 23148635 |
PQID | 1151794996 |
PQPubID | 23462 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_1328513845 proquest_miscellaneous_1328510316 proquest_miscellaneous_1171871624 proquest_journals_1151794996 gale_infotracmisc_A308233387 gale_infotracacademiconefile_A308233387 pubmed_primary_23148635 crossref_primary_10_2217_pgs_12_150 crossref_citationtrail_10_2217_pgs_12_150 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-11-00 2012-Nov 20121101 |
PublicationDateYYYYMMDD | 2012-11-01 |
PublicationDate_xml | – month: 11 year: 2012 text: 2012-11-00 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Pharmacogenomics |
PublicationTitleAlternate | Pharmacogenomics |
PublicationYear | 2012 |
Publisher | Future Medicine Ltd |
Publisher_xml | – name: Future Medicine Ltd |
References | e_1_3_4_3_17_1 e_1_3_4_3_16_1 e_1_3_4_3_15_1 e_1_3_4_3_14_1 e_1_3_4_3_19_1 e_1_3_4_3_18_1 e_1_3_4_3_21_1 e_1_3_4_3_22_1 e_1_3_4_3_9_1 e_1_3_4_3_23_1 e_1_3_4_3_24_1 James HM (e_1_3_4_3_27_1) 2008; 35 e_1_3_4_3_20_1 e_1_3_4_4_2_1 e_1_3_4_4_3_1 Takatori R (e_1_3_4_3_28_1) 2006; 24 Berkun Y (e_1_3_4_3_10_1) 2007; 34 e_1_3_4_3_2_1 e_1_3_4_3_29_1 e_1_3_4_3_1_1 e_1_3_4_3_4_1 e_1_3_4_3_3_1 e_1_3_4_3_7_1 e_1_3_4_3_25_1 e_1_3_4_3_8_1 e_1_3_4_3_26_1 e_1_3_4_3_5_1 e_1_3_4_3_6_1 e_1_3_4_3_32_1 e_1_3_4_3_33_1 e_1_3_4_3_34_1 e_1_3_4_3_13_1 e_1_3_4_3_12_1 e_1_3_4_3_11_1 e_1_3_4_3_30_1 e_1_3_4_3_31_1 |
References_xml | – ident: e_1_3_4_4_3_1 – ident: e_1_3_4_3_7_1 doi: 10.1002/art.21573 – ident: e_1_3_4_3_25_1 doi: 10.1186/1471-2105-9-557 – ident: e_1_3_4_3_11_1 doi: 10.1038/sj.tpj.6500438 – ident: e_1_3_4_3_2_1 doi: 10.1093/rheumatology/41.12.1367 – ident: e_1_3_4_3_32_1 doi: 10.1200/JCO.2008.20.4156 – ident: e_1_3_4_3_21_1 doi: 10.1006/mgme.2000.3034 – ident: e_1_3_4_3_19_1 doi: 10.1186/1477-7525-1-20 – ident: e_1_3_4_3_16_1 doi: 10.1038/ng1001-233 – ident: e_1_3_4_3_26_1 doi: 10.1002/art.20460 – ident: e_1_3_4_3_14_1 doi: 10.1038/tpj.2012.7 – ident: e_1_3_4_3_24_1 doi: 10.1006/meth.2001.1262 – ident: e_1_3_4_3_12_1 doi: 10.1007/s00228-008-0521-7 – ident: e_1_3_4_3_20_1 doi: 10.1159/000180580 – ident: e_1_3_4_4_2_1 – ident: e_1_3_4_3_22_1 doi: 10.1093/bioinformatics/bth457 – ident: e_1_3_4_3_15_1 doi: 10.1007/s00296-007-0339-0 – volume: 35 start-page: 562 issue: 4 year: 2008 ident: e_1_3_4_3_27_1 article-title: Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. publication-title: J. Rheumatol. – ident: e_1_3_4_3_29_1 doi: 10.1097/FPC.0b013e32833315d1 – ident: e_1_3_4_3_6_1 doi: 10.1002/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO;2-B – ident: e_1_3_4_3_1_1 doi: 10.1186/ar419 – ident: e_1_3_4_3_23_1 doi: 10.1093/nar/16.3.1215 – ident: e_1_3_4_3_5_1 doi: 10.1097/00008571-200204000-00002 – ident: e_1_3_4_3_31_1 doi: 10.1042/bj20020512 – ident: e_1_3_4_3_3_1 doi: 10.1093/rheumatology/39.9.975 – ident: e_1_3_4_3_8_1 doi: 10.1002/art.21726 – ident: e_1_3_4_3_33_1 – ident: e_1_3_4_3_9_1 doi: 10.1002/art.22129 – ident: e_1_3_4_3_4_1 doi: 10.1097/01.fpc.0000236326.80809.b1 – ident: e_1_3_4_3_13_1 doi: 10.1136/ard.2009.111567 – ident: e_1_3_4_3_17_1 doi: 10.1002/art.1780310302 – ident: e_1_3_4_3_30_1 doi: 10.1023/B:SCAM.0000007117.50428.63 – volume: 24 start-page: 546 issue: 5 year: 2006 ident: e_1_3_4_3_28_1 publication-title: Clin. Exp. Rheumatol. – ident: e_1_3_4_3_34_1 – volume: 34 start-page: 1664 issue: 8 year: 2007 ident: e_1_3_4_3_10_1 publication-title: J. Rheumatol. – ident: e_1_3_4_3_18_1 doi: 10.1136/ard.59.suppl_1.i28 |
SSID | ssj0021640 |
Score | 2.15871 |
SecondaryResourceType | review_article |
Snippet | We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based... Aim: We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a... Original submitted 23 May 2012; Revision submitted 3 September 2012 |
SourceID | proquest gale pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1583 |
SubjectTerms | Aged Analysis Antirheumatic Agents - administration & dosage Antirheumatic Agents - toxicity Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - genetics Biomarkers, Pharmacological Cell Line Drug therapy Drugs Female Genetic aspects Genetic Association Studies Haplotypes Health aspects Humans Linkage Disequilibrium Male Methotrexate Methotrexate - administration & dosage Methotrexate - toxicity Middle Aged Polymorphism, Single Nucleotide Reduced Folate Carrier Protein - genetics Rheumatoid arthritis Single nucleotide polymorphisms |
Title | Genetic Variation in the SLC19A1 gene and Methotrexate Toxicity in Rheumatoid Arthritis Patients |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23148635 https://www.proquest.com/docview/1151794996 https://www.proquest.com/docview/1171871624 https://www.proquest.com/docview/1328510316 https://www.proquest.com/docview/1328513845 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_B9sIL4puwMRmBhpAWrf5I4jyhMm2aEEwVbFLfgmM7WyWUlDadtv-eOydt2YT65AdfHMd3tn_n-H4H8EE74XW4qqNkCMlJYs0THcvUWu7RP8gCqc_3s_T0Qn0dJ-P-wG3eX6tcrolhoXaNpTPyQ0QuZDsIzz9P_8SUNYr-rvYpNB7CNkckQqkbsvHa4UJXYNBFF4kYd6q0oycViMIPp5dzOgbkFG__z4Z0f1m-BzbDpnPyBB73aJENO_U-hQe-fgb7o45u-vaAna-jp-YHbJ-N1kTUt8_hF3FKYxW7Roc4aIBNaoaIj_38dsTzIWdoPZ6Z2rGQSLqd-RuEnqxtbiYW0TlJz678AkFtM3EMjewqUCCxnox1_gIuTo7Pj07jPqNCbNENa2NTCWlKHMiyGmCpXOJzra1W6AQabYyoHNY7mVdZospK56VMy6TkGlVqE2nkS9iqm9q_BmYMd8o6UfrMqDTFkpuBTdPcIWLwAxHBp-WwFranG6esF78LdDtIBQWqoOCiQBVE8H4lO-1INv4r9ZG0U9DMw5as6QMIsD_EYVUMA_MOutxZBLt3JHHG2LvVS_0W_YzFd6zsK4J3q2p6km6h1b5ZkAzu5ES5pTbISKGJpZBvaifISK2SCF519rX6bsTbSiMKfLO5kzvwCKGb6KIid2GrnS38W4RHbbkX5sAebH85Phv9-AvK2A8s |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4a3QO8IO6EDTAChpAWrXac1HmYUBmbOtZVFXTS3jLHdlilKSm9wPrn-G0cO5exCfVtT3nwqZvkHNvf5_h8B-Cd0MwId1SHBy4lJ_QFDYUfREpRg_yg40R9jgdR74R_PQ1P1-BPnQtjj1XWc6KbqHWh7B75DiIXGzsIzz9Nfvq2apT9ulqX0JBVaQW96yTGqsSOI7P8jRRutnv4Bf39nrGD_dFez6-qDPgKqcnclxkLZIqdp1kbr1yHJhZCCY7ESAopWaaxXQdx1gl5mok4DaI0TKnAx1RhIAPs9w6sc7uB0oL1z_uD4beG8iEZaZf5TczHtTIqBVIZ8oCdyY-Z3YikNuP_nyXx5sJwA-66Ze_gAdyv8CrplgH2ENZM_gi2hqXg9XKbjK7yt2bbZIsMr6Swl4_hzKpaYxP5hZTcxQAZ5wQxJ_ne36NxlxKMX0NkrokrZT2fmksEv2ReXI4V8gNrPT03C4TVxVgTDPNzJ8JEKjnY2RM4uZW3_RRaeZGb50CkpJorzVLTkTyK8EplW0VRrBGzmDbz4GP9WhNVCZ7buhsXCRIf64IEXZBQlqALPHjb2E5KmY__Wn2w3kns2MeelKxSGPB-rIpW0nXaP0j6Ox5sXrPEMauuN9f-Tao5A_-jiXAP3jTN9pf2HFxuioW1QSxhRb_4CpuACauTSFf142wCwUMPnpXx1Tw3In4uEIe-WH2Tr-Fub3TcT_qHg6MNuIdAkpU5mpvQmk8X5iWCtXn6qhoRBM5uexD-BRzWUlQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4aQ0K8IO4LDDAChpAWtb4kcR4QqjaqjY2pEpvUt8yxHVYJJaVNYf1r_DqOnbRlE-rbnvLgE-dyju3vS3y-A_BWGmal36ojuE_JiUJJIxnyWGtqkR8kXtTn60l8cCa-DKPhBvxZ5MK4bZWLOdFP1KbS7ht5B5GLix2E552i3RYx2O9_Gv8MXQUp96d1UU6jCZEjO_-N9G368XAfff2Osf7n072DsK0wEGqkJXWoCsZVjh3nRRePwkQ2lVJLgaRISaVYYbDd8LRIIpEXMs15nEc5lfiIOuKKY7-34HbChXBlI5LhiuwhDek2mU0sxFUybqRRGTKAzvj71H2CpC7X_5_F8PqScA3o-gWvfx_utUiV9JrQegAbtnwIO4NG6nq-S05XmVvTXbJDBisR7PkjOHd61thEfiEZ994no5Ig2iTfjvdo2qMEI9cSVRrii1jXE3uJsJfU1eVIIzNw1pMLO0NAXY0MwQC_8PJLpBWCnT6Gsxt5109gs6xKuwVEKWqENiy3iRJxjEequjqOU4NoxXZZAB8WrzXTrdS5q7jxI0PK41yQoQsyyjJ0QQBvlrbjRuDjv1bvnXcyN-qxJ63a5AW8H6eflfW86g_S_SSA7SuWOFr11eaFf7N2tsBrLGM7gNfLZnem2wFX2mrmbBBFOLkvscaGM-kUEum6frwNlyIK4GkTX8vnRqwvJCLQZ-tv8hXcwaGXHR-eHD2Hu4ggWZOcuQ2b9WRmXyBKq_OXfjgQOL_p8fcX635P8A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+variation+in+the+SLC19A1+gene+and+methotrexate+toxicity+in+rheumatoid+arthritis+patients&rft.jtitle=Pharmacogenomics&rft.au=Bohanec+Grabar%2C+Petra&rft.au=Leandro-Garc%C3%ADa%2C+Luis+J&rft.au=Inglada-P%C3%A9rez%2C+Luc%C3%ADa&rft.au=Logar%2C+Du%C5%A1an&rft.date=2012-11-01&rft.pub=Future+Medicine+Ltd&rft.issn=1462-2416&rft.volume=13&rft.issue=14&rft.spage=1583&rft_id=info:doi/10.2217%2Fpgs.12.150&rft.externalDocID=A308233387 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-2416&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-2416&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-2416&client=summon |